Latest Insider Transactions at Regenxbio Inc. (RGNX)
This section provides a real-time view of insider transactions for Regenxbio Inc. (RGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENXBIO Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENXBIO Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-46.98%
|
$100,000
$10.11 P/Share
|
|
Oct 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Sep 16
2024
|
Mitchell Chan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,869
+50.0%
|
-
|
|
Sep 03
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-24.77%
|
$110,000
$11.92 P/Share
|
|
Sep 03
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Aug 08
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
36,316
+7.56%
|
$0
$0.85 P/Share
|
|
Aug 01
2024
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,386
+26.07%
|
-
|
|
Aug 01
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,867
+24.13%
|
-
|
|
Aug 01
2024
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$1,500
$15.0 P/Share
|
|
Aug 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,100
-16.39%
|
$141,400
$14.35 P/Share
|
|
Aug 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,100
+16.21%
|
$80,800
$8.25 P/Share
|
|
Aug 01
2024
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,446
+24.69%
|
-
|
|
Jul 29
2024
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,648
-5.37%
|
$144,720
$15.04 P/Share
|
|
Jul 29
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
11,000
-49.36%
|
$165,000
$15.04 P/Share
|
|
Jul 29
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+33.05%
|
$132,000
$12.74 P/Share
|
|
Jul 25
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,369
-3.63%
|
$199,797
$13.96 P/Share
|
|
Jul 25
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,369
+3.5%
|
$46,107
$3.76 P/Share
|
|
Jul 24
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
12,221
-2.91%
|
$158,873
$13.78 P/Share
|
|
Jul 24
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
12,221
+2.83%
|
$36,663
$3.76 P/Share
|
|
Jul 17
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
2,210
-0.54%
|
$28,730
$13.77 P/Share
|
|
Jul 17
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
2,210
+0.54%
|
$6,630
$3.76 P/Share
|
|
Jul 16
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
200
-0.05%
|
$2,600
$13.76 P/Share
|
|
Jul 16
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.05%
|
$600
$3.76 P/Share
|
|
Jul 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-46.98%
|
$110,000
$11.27 P/Share
|
|
Jul 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Jul 01
2024
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,458
+23.9%
|
-
|
|
Jun 28
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,363
+1.07%
|
$12,267
$9.95 P/Share
|
|
May 31
2024
|
Daniel Tasse |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Allan M. Fox |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Alexandra Glucksmann |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Argeris N Karabelas |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
George V Migausky |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Jennifer Zachary |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+25.1%
|
-
|
|
May 31
2024
|
David C Stump |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$225,000
$15.81 P/Share
|
|
May 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Apr 15
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$270,000
$18.19 P/Share
|
|
Apr 15
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Mar 19
2024
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,041
+7.52%
|
$60,123
$3.76 P/Share
|
|
Mar 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$315,000
$21.86 P/Share
|
|
Mar 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Mar 05
2024
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,878
-10.73%
|
$360,584
$28.36 P/Share
|
|
Mar 05
2024
|
Steve Pakola Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,878
+9.69%
|
$283,316
$22.25 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-1.79%
|
$240,000
$16.67 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
45,000
-9.93%
|
$675,000
$15.18 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+9.04%
|
$135,000
$3.76 P/Share
|
|
Jan 03
2024
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,237
-13.85%
|
$293,029
$17.39 P/Share
|
|
Jan 02
2024
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,462
+23.77%
|
-
|